Modality
Vaccine
MOA
EZH2i
Target
TNFα
Pathway
PI3K/AKT
FSGS
Development Pipeline
Preclinical
~Jan 2023
→ ~Apr 2024
Phase 1
Jul 2024
→ Jun 2030
Phase 1Current
NCT08715152
1,016 pts·FSGS
2024-07→2030-06·Completed
1,016 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-284.2y awayPh2 Data· FSGS
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2030-06-28 · 4.2y away
FSGS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08715152 | Phase 1/2 | FSGS | Completed | 1016 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |